Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $43.9 million.

  • Insight Molecular Diagnostics' Liabilities and Shareholders Equity fell 37.43% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.9 million, marking a year-over-year decrease of 34.70%. This contributed to the annual value of $35.1 million for FY2024, which is 53.16% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Liabilities and Shareholders Equity of $43.9 million as of Q3 2025, which was down 13.03% from $50.5 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Liabilities and Shareholders Equity high stood at $177.4 million for Q2 2021, and its period low was $35.1 million during Q4 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $70.6 million (2024), whereas its average is $65.0 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Liabilities and Shareholders Equity soared by 191.37% in 2021 and then plummeted by 53.16% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Liabilities and Shareholders Equity (Quarterly) stood at $159.6 million in 2021, then crashed by 37.27% to $100.1 million in 2022, then dropped by 25.18% to $74.9 million in 2023, then slumped by 53.16% to $35.1 million in 2024, then plummeted by 37.43% to $43.9 million in 2025.
  • Its last three reported values are $43.9 million in Q3 2025, $50.5 million for Q2 2025, and $60.4 million during Q1 2025.